Lactobacillus fermentum Lferm-1 and application thereof
Lactobacillus fermentation Lferm-1 inhibits pathogenic bacteria and proinflammatory factors and repairs the intestinal barrier, solving the existing problems of major side effects of chemotherapy-related diarrhea, achieving safe and efficient treatment effects.
Patent Information
- Application Number
- CN202410604959.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-15
- Publication Date
- 2024-11-22
AI Technical Summary
The existing drugs for the treatment of chemotherapy-related diarrhea have great side effects and lack targeted and multi-mechanical treatment plans, which cannot effectively repair intestinal mucosal damage and anti-inflammatory.
Lactobacillus fermentation mucosa Lferm-1 is used to repair the intestinal barrier and alleviate the inflammatory response of colon tissue by inhibiting pathogenic bacteria, proinflammatory factors and inflammatory infiltration. It is used as a new probiotic preparation for preventing and treating chemotherapy-related diarrhea. .
Lactobacillus fermented mucinous Lferm-1 has safety, antioxidant functions, inhibits the growth of pathogenic bacteria, repairs barrier damage caused by drug-induced diarrhea, significantly reduces inflammatory response, and achieves a therapeutic effect comparable to traditional drugs without gastrointestinal side effects.
Smart Images

Figure CN118995465A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of microbial drugs and relates to a fermented Lactobacillus mucosa Lferm-1 and an application thereof, and specifically relates to a fermented Lactobacillus mucosa Lferm-1 and an application thereof in preventing or treating chemotherapy-related diarrhea. Background Art
[0002] Chemotherapy-induced diarrhea (CID) is a common gastrointestinal toxicity caused by chemotherapy in cancer patients. Mild diarrhea can reduce the patient's quality of life, and frequent severe diarrhea may cause dehydration, infection, shock, and even death. Therefore, patients with severe diarrhea need to reduce the dose of chemotherapy drugs or even interrupt chemotherapy, which affects the treatment of tumors. According to data released by the International Agency for Research on Cancer under the World Health Organization, there will be approximately 19.3 million new cancer cases worldwide in 2020, and forecasts show that in 2040, the number of new cancer cases worldwide will reach 28.4 million. As many as 82% of cancer patients will suffer from diarrhea-related side effects. For different patients, although the breadth and severity of CID vary greatly, the incidence of diarrhea caused by fluorouracil (Fluorouracil) and irinotecan (Irinotecan, CPT-11) is the highest, reaching 80%.
[0003] Both 5-fluorouracil (5-FU) and irinotecan can cause acute damage to the intestinal mucosa, leading to epithelial loss. 5-FU can cause mitotic arrest in crypt cells, leading to an increase in the ratio of immature secretory crypt cells to mature villus enterocytes, resulting in secretory diarrhea. Irinotecan-induced intestinal mucosal changes are associated with apoptosis and goblet cell hyperplasia. These changes may be related to the accumulation of SN-38, the active metabolite of irinotecan, in the intestinal mucosa.
[0004] At present, there is a lack of targeted drugs for the treatment of chemotherapy-related diarrhea in clinical practice. All symptomatic treatments are with drugs such as opioids, somatostatin analogs, glucocorticoids, bile acid sequestrants, and antibiotics. However, these drugs have a single mechanism of action and have large side effects when used for a long time. For example, opioids (loperamide) may cause the risk of paralytic ileus when used in large doses; somatostatin analogs (octreotide) may cause side effects such as gallstones, hyperglycemia, and impaired glucose tolerance; glucocorticoids may have systemic effects, increase the risk of infection, and aggravate viral or bacterial infections; bile acid sequestrants are suitable for diarrhea caused by bile acid malabsorption or excessive lipids, but they may cause gastrointestinal side effects such as abdominal distension, flatulence, and constipation. Therefore, there is an urgent need to develop new, safer and more effective drugs to prevent or treat chemotherapy-related diarrhea.
[0005] Probiotics have long been used in the treatment of diarrhea, such as Mommy Love (Bacillus subtilis combined live bacteria), Yijunkang (compound Lactobacillus acidophilus), Zhengchangsheng (Bacillus licheniformis live bacteria), Bifidobacterium triple live bacteria, Jinbifidobacterium (Bifidobacterium lactobacillus triple live bacteria), etc. In some patents, such as CN115484968A, CN104146182A, CN101646452A, CN1511945A and CN86103736A, the use of various probiotics including fermented lactobacillus in the treatment or prevention of diarrhea has also been studied. These probiotics mainly improve diarrhea symptoms by inhibiting pathogens, regulating disordered intestinal flora, and restoring a healthy microecological environment. However, no studies have shown that these probiotics can play an effective therapeutic role against CID by repairing intestinal mucosal damage and anti-inflammatory effects.
[0006] Therefore, it is necessary to explore the therapeutic effects of new probiotics on CID and provide alternatives to existing treatments with low toxicity and side effects and the ability to work from multiple mechanisms. Summary of the invention
[0007] The present invention aims at the deficiencies of existing clinical treatment methods and provides a probiotic. The probiotic of the present invention is safe, can inhibit pathogenic bacteria and pro-inflammatory factors, repair the intestinal barrier, and reduce inflammatory infiltration of colon tissue, thereby achieving the effect of effectively treating CID.
[0008] In order to solve the problems existing in the prior art, the first aspect of the present invention provides a biomaterial, wherein the biomaterial is selected from the following M1, M2, M3 and M4;
[0009] M1: fermented Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof;
[0010] M2: progeny strain of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or its lysate;
[0011] M3: a cloned strain of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof;
[0012] M4: pure culture of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof.
[0013] A second aspect of the present invention provides a method for culturing fermented mucus Lactobacillus, the method comprising: inoculating a fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, a progeny strain of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, a cloned strain of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, or a pure culture of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352 into a culture medium, performing proliferation culture, and obtaining proliferated fermented mucus Lactobacillus.
[0014] The third aspect of the present invention provides a composition, wherein the composition uses the biomaterial described in the first aspect of the present invention as an active material.
[0015] In some embodiments, the composition further contains an auxiliary material.
[0016] In some embodiments, the auxiliary material is selected from any one of the following materials:
[0017] Bacterial culture medium;
[0018] Lyoprotectants;
[0019] Pharmaceutically acceptable carriers or excipients;
[0020] Acceptable materials in health products;
[0021] acceptable materials in cosmetics;
[0022] Materials acceptable in food.
[0023] The fourth aspect of the present invention provides use of the biomaterial described in the first aspect of the present invention or the composition described in the third aspect of the present invention in preparing a product for use alone or in combination with other microbial agents and / or drugs to improve the health of a subject;
[0024] The improving the health condition of the subject is selected from:
[0025] Treat, prevent and / or relieve chemotherapy-induced diarrhea;
[0026] Treating, preventing and / or slowing down chemotherapy-induced colon damage in subjects;
[0027] Inhibiting the proliferation of any one, any two, any three or four of Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile in the body cavity of the subject;
[0028] Treat, prevent and / or alleviate tissue damage, disease or sub-health condition caused by any one, any two, any three or four of Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile;
[0029] Treating, preventing and / or alleviating tissue damage, disease or sub-health condition caused by increased expression of any one, any two or three of IFN-γ, TNF-α and IL-6;
[0030] Improve the antioxidant capacity in the intestines of subjects.
[0031] In some embodiments, the product is a pharmaceutical product.
[0032] In some embodiments, the product is a health product.
[0033] In some embodiments, the product is a food product.
[0034] In some embodiments, the subject is selected from a human and a mouse.
[0035] In some embodiments, the chemotherapy drug is selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.
[0036] In some embodiments, the chemotherapy drug is selected from doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, cisplatin, carboplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, 5-fluorouracil, and irinotecan.
[0037] The fermented mucus lactobacillus of the present invention has the following characteristics:
[0038] 1) No hemolysis;
[0039] 2) Resistant to gastric acid (pH 3.0);
[0040] 3) Has antioxidant properties
[0041] 4) It can inhibit the expression of pro-inflammatory factors;
[0042] 5) Alleviate intestinal epithelial damage caused by toxicity of chemotherapy drugs.
[0043] Beneficial effects of the present invention:
[0044] 1. The fermented mucus lactobacillus Lferm-1 of the present invention has no toxic factors, is non-hemolytic, and has good safety;
[0045] 2. It has antioxidant function and can reduce the damage caused by oxidative stress caused by chemotherapy drugs;
[0046] 3. It has an inhibitory effect on a variety of pathogenic bacteria, regulates intestinal flora, and inhibits the growth of pathogenic bacteria;
[0047] 4. It can alleviate or reduce the barrier dysfunction caused by inflammatory factors, and has a repairing effect on the barrier damage caused by drug-induced diarrhea;
[0048] 5. Inhibit the expression of pro-inflammatory factors and reduce intestinal inflammatory response;
[0049] 6. The fermented mucus lactobacillus Lferm-1 of the present invention achieves an effect equivalent to that of the chemical drug loperamide in the total score index of diarrhea, and does not have the side effect of inhibiting gastrointestinal motility, and can meet the needs of tumor patients for long-term use. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 This is a front view of the colony morphology of the fermented mucus lactobacillus Lferm-1 of the present invention.
[0051] Figure 2 The results of in vitro antioxidant test of Lactobacillus mucilaginosus Lferm-1 are shown.
[0052] Figure 3 The results of the antibacterial test of fermented Lactobacillus mucilaginosus Lferm-1 against various pathogenic bacteria are shown.
[0053] Figure 4 The results of the in vitro cell inflammation inhibition test of fermented Lactobacillus mucilaginosus Lferm-1 are shown, A is the result of the effect on IL-6 expression, and B is the result of the effect on TNF-α expression.
[0054] Figure 5 The figure shows the therapeutic effect of each experimental group on mice with diarrhea caused by 5-fluorouracil. A is the diarrhea score curve of each group from day 1 to day 9; B is the total diarrhea score of each group.
[0055] Figure 6 The effect of each experimental group on the pathological damage of the colon in mice with 5-fluorouracil-induced diarrhea is shown. A is the HE staining result of each group; B is the total pathological score of each group.
[0056] Figure 7 The effect of each experimental group on the expression of TNF-α gene in the colon of mice with 5-fluorouracil-induced diarrhea is shown. DETAILED DESCRIPTION
[0057] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.
[0058] Unless otherwise specified, the terms used herein have the common meanings in the biomedical field.
[0059] The specific temperature parameters in the present invention, unless otherwise specified, should be understood as constant temperature treatment, and are allowed to fluctuate within a certain temperature range, such as within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C.
[0060] Diarrhea refers to a clinical symptom in which the frequency of bowel movements significantly exceeds the usual habit (>3 times / d), the feces are thin, the water content is increased (>85%), and the stool may be accompanied by mucus, pus, blood, or undigested food. In the present invention, its meaning covers antibiotic-related diarrhea, chemotherapy-related diarrhea, functional diarrhea, infectious diarrhea, etc.
[0061] Chemotherapy refers to the use of drugs to kill tumor cells to achieve treatment goals. It is the main means of treating tumors besides surgery and radiotherapy.
[0062] Chemotherapy-related diarrhea refers to diarrhea caused by gastrointestinal toxicity of chemotherapy drugs, including but not limited to non-targeted small molecule drugs, targeted small molecule drugs, biological macromolecule drugs, nucleic acid drugs and cell therapy drugs. Examples of these drugs include, but are not limited to, antibiotic chemotherapy drugs, such as doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin and their derivatives, taxane chemotherapy drugs, such as paclitaxel, docetaxel, albumin-paclitaxel and their derivatives, etc.; platinum chemotherapy drugs, such as cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin and their derivatives, etc.; alkylating agent chemotherapy drugs, such as cyclophosphamide, nitrogen mustard, carmustine and their derivatives, etc.; camptothecin chemotherapy drugs, such as camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives, etc.; antimetabolite chemotherapy drugs, such as capecitabine, gemcitabine, methotrexate, fluorouracil, pemetrexed, cytarabine and their derivatives, etc.; targeted drugs, such as apatinib, axitinib, cabozantinib, sorafenib, sunitinib, etc.; anti-PD-1PD- / L1 antibodies, such as nivolumab and pembrolizumab.
[0063] Several types refers to two or more types that are integers, such as two, three, four, five, six, seven...etc.
[0064] The fermented mucus lactobacillus Limosilactobacillus fermentum of the present invention can be live bacteria, or inactivated bacteria, or pure culture, lysate, fermentation product, culture fluid (such as supernatant) of bacteria, or components extracted from the culture.
[0065] In some embodiments, the fermented Lactobacillus fermentum is a live bacterium, an inactivated bacterium, or a combination thereof (i.e., a combination of live and inactivated bacteria). The inactivated bacteria may be an inactivated bacterium with a complete morphological structure, an inactivated bacterium with an incomplete morphological structure, or a combination thereof.
[0066] The fermented mucus lactobacillus Limosilactobacillus fermentum of the present invention includes the strain Limosilactobacillus fermentum Lferm-1 with a deposit number of CCTCC NO: M 2023352, and its progeny strains (offspring) or strains cultured (cloned) from the original strain. The progeny strains and cloned strains have similar activities to Lferm-1. Fermented mucus lactobacillus is also called fermented lactobacillus.
[0067] The present invention provides a pharmaceutical composition, which contains a therapeutically or preventively effective amount of fermented Lactobacillus mucilaginosus Lferm-1 and a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical composition is used for the treatment and prevention of diarrhea. Further, the pharmaceutical composition is used for the treatment and prevention of chemotherapy-related diarrhea.
[0068] The invention provides a food composition, which contains fermented mucus lactobacillus Lferm-1, and food-acceptable additives and food raw materials.
[0069] The therapeutically effective amount or prophylactically effective amount is an amount that can achieve the desired therapeutic or prophylactic result clinically. In some embodiments, the therapeutically effective amount does not induce or cause undesirable side effects. In some embodiments, the therapeutically effective amount induces or causes side effects, but only causes side effects that are acceptable to the treating clinician in view of the patient's condition. In some embodiments, a single dose or a single effective amount contains 10 2 ~10 15 CFU, 10 3 ~10 14 CFU, 10 4 ~10 13 CFU, 10 5 ~10 12 CFU, 10 6 ~10 12 CFU of Lactobacillus mucilaginosus.
[0070] A pharmaceutically acceptable carrier refers to a pharmaceutical carrier that does not cause significant stimulation to a subject and does not eliminate the biological activity and characteristics of the probiotics administered. A pharmaceutically acceptable carrier can enhance or stabilize the composition, or can be used to promote the preparation of the composition. A pharmaceutically acceptable carrier may include solvents, dispersion media, coatings, surfactants, antioxidants, isotonic agents, absorption delay agents, salts, drug stabilizers, binding agents, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. and combinations thereof, as known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, the 18th edition Mack Printing Company, 1990, pages 1289-1329). Unless conventional carriers are incompatible with active ingredients, it is considered to be used in therapeutic or pharmaceutical compositions. The carrier may be selected to minimize adverse side effects of the subject and / or minimize the inactivation of the active ingredient.
[0071] Excipients refer to substances added to pharmaceutical compositions to give the drug a certain shape or concentration, such as sterile water, physiological saline, polyalkylene glycols (such as polyethylene glycol), vegetable oils or hydrogenated naphthalene, calcium bicarbonate, calcium phosphate, various sugars, various types of starch, cellulose derivatives, gelatin, etc.
[0072] The pharmaceutical composition of the present invention may further contain a second beneficial active ingredient, such as another probiotic, prebiotic or drug with antidiarrhea function, and the prebiotic helps regulate the intestinal environment by promoting the growth of probiotics in the intestine, thereby indirectly playing an antidiarrhea effect. Examples of the second beneficial active ingredient include, but are not limited to, Bacillus licheniformis, Bifidobacterium, Clostridium butyricum, oligofructose, galacto-oligosaccharide, isomaltooligosaccharide, oligoxylose, oligomannose, inulin, stachyose, soybean oligosaccharide, beta-glucan, oligolactose, etc.
[0073] In some embodiments, the pharmaceutical composition is in the form of tablets, capsules, granules, solutions, suspensions, powders, etc.
[0074] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work should fall within the scope of protection of the present invention.
[0075] The culture medium preparation method used in the following examples is as follows:
[0076] Preparation of YCFA medium: weigh 10.0 g of casein peptone, 2.5 g of yeast extract, 0.45 mL of MgSO4·7H2O (10% mother solution), 0.45 mL of CaCl2 (10% mother solution), 10 mL of TE141, 2 HPO 4 0.45g, KH 2 PO 4 0.45 g, NaCl 0.90 g, VFA-mix 3.2 mL, dissolved in 1 L of distilled water, N 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, store in a cool, dry place for later use.
[0077] Preparation of TE141: Weigh 1.50 g of nitrilotriacetic acid and add it to 200 mL of pure water. Add an appropriate amount of NaOH until the solution becomes clear. Then add 800 mL of water and adjust the pH value to 5.5 with 50% HCl. Then weigh MgSO 4 7H 2 O 3.00g, MnSO 4 ·H 2 O 0.50 g, NaCl 1.00 g, FeSO 4 7H 2 O 0.10g, CoSO 4 7H 2 O0.18g, CaCl 2 ·2H 2 O 0.10g, ZnSO 4 7H 2 O 0.18 g, CuSO 4 ·5H 2 O 0.006g, KAl(SO 4 ) 2 12H 2 O0.02g, H 3 BO 3 0.01g, Na 2 MoO 4 ·2H 2 O 0.01g, NiCl 2 6H 2 O 0.03g, Na 2 SeO 3 ·5H 2 O 0.03mL (10mg / mL stock solution), Na 2 WO 4 ·2H 2O 0.03mL (10mg / mL stock solution) was added to the above test solution. Stir continuously during the addition process to keep the solution clear for later use.
[0078] Preparation of VFA-mix: Measure 90 mL of acetic acid, 30 mL of propionic acid, 10 mL of n-valeric acid, 10 mL of isobutyric acid, and 10 mL of butyric acid, mix well for later use, and adjust to neutrality with 5 M NaOH before use.
[0079] Preparation of triple-mixed liquid medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3), and dissolve them in 1 L of distilled water. 2 Replace and deoxygenate, package, sterilize at 121℃ for 30 minutes, and store in a cool, dry place. When preparing the three-mix solid culture medium, add 5g of agar powder to the three-mix liquid culture medium.
[0080] Preparation of the second mixed culture medium (BHI+MRS): Weigh 19.25 g of BHI broth powder, 27.0 g of MRS broth powder, and 0.5 g of cysteine hydrochloride monohydrate (Longteng Biotechnology Co., Ltd.), dissolve in 1 L of distilled water, deoxygenate and package, sterilize at 121°C for 15 min, and store in a cool and dry place.
[0081] Preparation of BF839 medium: weigh 6.0 g of potato extract powder (Beijing Solebow Technology Co., Ltd., FA0270), 10.0 g of polyvalent peptone (Beijing Solebow Technology Co., Ltd., P8950-250), Peptone (HB8277, Qingdao Hi-Tech Industrial Park Haibo Biotechnology Co., Ltd.) 5.0 g, sodium thioglycolate (Shanghai Aladdin Biochemical Technology Co., Ltd., S105664-25G) 0.3 g, yeast extract powder (Thermo Fisher Oxoid, LP0021B) 5.0 g, glucose (50-99-7, Chengdu Kelong Chemical Co., Ltd.) 1.5 g, disodium hydrogen phosphate (7558-79-4, Chengdu Kelong Chemical Co., Ltd.) 4.0 g were dissolved in 1 L of distilled water, N 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 30min, and store in a cool, dry place.
[0082] Preparation of artificial gastric juice: adjust the pH of artificial gastric juice (Shanghai Yuanye Biotechnology Co., Ltd., R30387, containing 10 g / L pepsin) to 3.0 and continuously pass N 21h. Sterilize with a 0.22μm filter in an anaerobic glove box and keep aside. Store at 4℃ for no more than 30 days.
[0083] Preparation of oxygen-free PBS: Weigh 0.27 g potassium dihydrogen phosphate, 1.42 g disodium hydrogen phosphate, 8 g sodium chloride, and 0.2 g potassium chloride, dissolve in 1 L of distilled water, heat to boil, cool to room temperature, add 0.55 g cysteine hydrochloride, stir to dissolve, adjust pH to 6.5, install a quantitative dispenser, and pass N 2 , heat to boiling, keep at a slight boiling state for 30 minutes, and after cooling, divide into 400mL / bottle, sterilize at 121℃ high temperature and wet heat for 30 minutes, and store in a cool and dry place for use.
[0084] GAM solid culture medium, TSB (Tryptone Soy Broth, Qingdao Haibo Biotechnology Co., Ltd., HB4114), and TSA (Tryptone Soy Agar, Qingdao Haibo Biotechnology Co., Ltd., HB4138) culture medium were prepared by weighing and dissolving according to the instructions, sterilizing with high temperature and wet heat at 121°C for 30 min, and storing in a cool and dry place.
[0085] Preparation of fermentation medium with bacterial powder: weigh 30g of anhydrous glucose, 15g of soy peptone, 10g of yeast extract powder, 5g of sodium acetate, 2g of potassium dihydrogen phosphate, 2g of disodium hydrogen phosphate, 0.1g of magnesium sulfate, 0.045g of manganese sulfate, 1mL of Tween 80, and 0.5g of monohydrated cysteine hydrochloride, and dissolve them in 1L of purified water. 2 Replace and deoxygenate, repackage, sterilize at 121℃ for 15min, and store in a cool, dry place.
[0086] Example 1: Isolation and Identification of Fermented Mucus Lactobacillus Lferm-1
[0087] The screening and separation method of Limosilactobacillus fermentum Lferm-1 is as follows:
[0088] Collect fresh stool samples from healthy volunteers, add appropriate amount of PBS to resuspend, and shake until the sample is fully resuspended. 2 Under the protection of the lysate, filter twice through gauze, and dispense the filtrate into 50mL centrifuge tubes. Centrifuge at 10000rpm for 20min and discard the supernatant. Add an appropriate amount of PBS to resuspend the bacteria in the centrifuged precipitate, then add an equal volume of 50% anaerobic glycerol aqueous solution to mix thoroughly, and dispense into 2mL screw cap tubes, 0.5mL each. After dispensing, bag and vacuum-pack in a -80℃ refrigerator for later use.
[0089] When separating, take out one frozen sample tube, resuspend the thawed sample in PBS (tenfold dilution) at a volume ratio of 1:10 for the sample to anaerobic PBS, vortex and shake for 5 minutes, transfer to the anaerobic glove box, take 0.5mL of bacterial suspension and shake in 4.5mL PBS to mix. Use the same tenfold dilution method as above to dilute the sample to 10 -6 , take appropriate bacterial solution gradient and mix with YCFA medium, then divide into 384-well plates and culture for one week. Pick the bacterial solution from the growing wells for transfer. After 48 hours of culture, divide the bacterial solution into two parts. One part is detected by MALDI-TOF-MS to preliminarily classify the isolated strains. When it can be successfully classified, the corresponding other part is transferred to a 96-well plate again according to the mass spectrometry results. After 48 hours of culture, one plate is amplified for 16S rDNA sequence and sequenced by Beijing Qingke Biotechnology Co., Ltd. Chengdu Branch. The other plate is mixed with 50% glycerol aqueous solution at a volume ratio of 1:1 and temporarily stored for use after the PCR results are confirmed.
[0090] The 16S rDNA sequencing results of several isolated strains were analyzed and compared with the NCBI nt library. The results showed that the sequence had the highest similarity (100%) with a strain of Limosilactobacillus fermentum. It was preliminarily identified as Limosilactobacillus fermentum and named Lactobacillus fermentum Lferm-1 (abbreviated as Lferm-1). Its colony morphology is white, opaque, and circular, with a convex center and a smooth and moist surface. The front photo is shown in Figure 1 .
[0091] The Lferm-1 strain was submitted and deposited in the China Center for Type Culture Collection (CCTCC) on March 17, 2023. The strain preservation number is: CCTCC NO: M 2023352, the culture name is: Limosilactobacillusfermentum Lferm-1, the Chinese classification name is: Fermented Lactobacillus, and the English classification name is: Limosilactobacillus fermentum. Its viability was tested by the China Center for Type Culture Collection (CCTCC) on March 24, 2023, and the result was survival.
[0092] Example 2: Whole genome analysis of Lactobacillus fermentans Lferm-1
[0093] The fermented mucus Lactobacillus Lferm-1 was inoculated into a three-mixed liquid medium and cultured until the late logarithmic growth period. The whole genome DNA of the strain was extracted and the whole genome was sequenced using the Illumina high-throughput sequencing platform NovaSeq 6000. After assembly and annotation, the protein sequence was entered into the Virulence Factor Databases (VFDB) for virulence factor analysis. The results showed that the bacteria did not have virulence factors.
[0094] The novelty of the strain was analyzed by using the Average Nucleotide Identity (ANI). By searching in Genbank, 126 published complete genomes of Limosilactobacillusfermentum were found. By comparing with fastANI (v1.33), it was found that the two strains closest to the complete genome of the fermentation Lactobacillus mucilaginosus Lferm-1 were GCA_003465085.1 (ANI = 99.32%) and GCA_024385625.1 (ANI = 99.29%), so the fermentation Lactobacillus mucilaginosus Lferm-1 can be considered a new strain. Its 16S rDNA sequence is shown in the following sequence 1 (shown in SEQ ID NO.1).
[0095] Sequence 1:
[0096]
[0097] The whole genome was annotated by emapper-2.1.9, and it was found that Lferm-1 contained genes encoding acetate-related enzymes. The sequence of the acetate-related enzyme is shown in the following sequence 2 (SEQ ID NO.2).
[0098] Sequence 2:
[0099] MKKTKIVSTLGPASTDVDTIVKLINAGANIFRFNFSHGDHPEHLGRIENVHKAEEITGKHVGIMLDTKGAEIRTTVQKEGKIEFNIGDKVRISMDDSLE GTKEKIAVTYAGLFDDVHEGGHVLFDDGLLDMLVDEKDEANKELVCHVLNHGILGSRKGVNAPGVSINLPGITEKDTSDINFGLDNGINFIAASFVRKPQDIEDIRVLLREKNMEDVQIFPKIESQEGIDNFEAIIEVADGLMVPRGDMGVEIPAENVPLVQKNMIRRCNELGKPVITATQMLDSMQ ENPRPTRAEVSDVANAVFDGTDATMLSGESANGDYPVESVATMNRIDIKAENNLDKFGREVFDFDKSDVTETIGSAVATAARDLGVKAIVAATASGYTARMISKYRPSADILALTFDERTERGLMINWGVQPYVVEKPTSTDEMFELASKKAKDLGFANVGDKIIVVAGLPIGQHGTTNMMRVQEVK
[0100] Example 3: Hemolysis test of fermented Lactobacillus mucilaginosus Lferm-1
[0101] The preserved fermented mucus lactobacillus Lferm-1 was inoculated into a three-mixed liquid medium and cultured anaerobically at 37°C until the late logarithmic growth period to obtain an activated strain. The bacterial suspension after resuspending 2mL2% fresh rabbit red blood cell suspension (Beijing Borsi Technology Co., Ltd.) and 2mL0.9% sterile saline (Shandong Qidu Pharmaceutical Co., Ltd.) was tested by liquid contact method, with an equal volume of sterile water as a positive control (hemoglobin is released after red blood cells absorb water and burst), and an equal volume of sterile saline as a negative control. Three parallels were set for each group, and each sample was photographed after standing for 24 hours. The results showed that the negative control was not hemolytic, the positive control was hemolytic, and the fermented mucus lactobacillus Lferm-1 bacterial suspension had no hemolysis, which met the basic requirements for the safety of intestinal probiotics.
[0102] Example 4: Gastric acid resistance of fermented Lactobacillus mucilaginosus Lferm-1
[0103] Inoculate the fermented mucus Lactobacillus Lferm-1 into the three-mixed liquid medium and culture it to the late logarithmic growth stage. Take 1 mL of the cultured bacterial solution and centrifuge it (8000 rpm, 5 min). After discarding the supernatant, resuspend the bacteria with 1 mL of pH 3.0 artificial gastric juice and incubate anaerobically at 37°C for 3 h. Resuspend the bacteria with 1 mL of anaerobic PBS as a control. Take appropriate amounts of the incubated bacterial suspension and dilute it 10 times with anaerobic PBS. Take 10 -4 ~10 -6 50 μL of the gradient bacterial suspension was mixed with a three-mix solid medium containing 0.5% agar powder, and cultured anaerobically at 37°C until a single colony grew and then counted. The survival rate of the strain resistant to gastric juice = (the number of viable bacteria in the gastric juice incubation group / the number of viable bacteria in the PBS incubation group) × 100%. Three parallels were set for each group, and the test results were expressed as Mean ± SEM.
[0104] The experimental results showed that the number of viable bacteria of Lactobacillus mucilaginosus Lferm-1 incubated in anaerobic PBS for 3 h was (3.40±0.17)×10 8 CFU / mL; after treatment with pH 3.0 artificial gastric juice, the number of viable bacteria was (3.42±0.52)×10 8 CFU / mL, and the tolerance rate to pH 3.0 artificial gastric juice was 100.49±15.23%. Lactobacillus mucis Lferm-1 has strong tolerance to pH 3.0 gastric juice and has the basic property of being a probiotic and not being digested in the intestine.
[0105] Example 5: Antioxidant experiment of fermented Lactobacillus mucilaginosus Lferm-1
[0106] The preserved fermentative mucus Lactobacillus Lferm-1 was activated and inoculated into BF839 medium, and Lactobacillus rhamnosus GG (Lactobacillus rhamnosus, CICC6141, China Industrial Microbiological Culture Collection Management Center) was used as a positive control. All strains were anaerobically cultured in BF839 medium at 37°C for 24 h.
[0107] Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, and resuspend with 0.5mL of the extract (pre-cooled) in the total antioxidant capacity detection kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315); transfer to a sterile screw-cap tube containing beads (Sigma-Aldrich Company, G4649-1KG), oscillate and break the wall once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), centrifuge at 12000rpm and 4℃ for 10min, and take the supernatant and place it on ice for testing.
[0108] A BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect BCA samples according to the instructions of the kit.
[0109] The total antioxidant capacity detection kit of strains was used to determine the antioxidant capacity of the samples according to the instructions of the kit and the standard curve. The total antioxidant capacity unit is μmol / mg prot.
[0110] The experimental results can be found in Figure 2 :Depend on Figure 2 It can be seen that the total antioxidant capacity of strain Lferm-1 reached 0.345±0.056μmol / mg prot, which is comparable to that of the positive control strain Lactobacillus rhamnosus GG, indicating that Lferm-1 has antioxidant capacity in vitro.
[0111] Example 6: Antibacterial ability of fermented Lactobacillus mucilaginosus Lferm-1 against pathogenic bacteria
[0112] In this example, four common pathogenic bacteria that cause diarrhea were selected for antibacterial ability testing. The source information of the pathogenic strains is as follows:
[0113] Salmonella paratyphi B (CMCC(B)50094) was purchased from China Food and Drug Inspection Institutes.
[0114] Staphylococcus aureus (CMCC(B)26003) was purchased from China Food and Drug Inspection Institutes.
[0115] Yersinia enterocolitica CMCC(B)52204 was purchased from China Food and Drug Inspection Institutes.
[0116] Clostridium difficile (CICC 22951) was purchased from China Industrial Microbiological Culture Collection Center.
[0117] Obtaining fermentation broth of Lactobacillus mucilaginosus: After being activated, Lactobacillus mucilaginosus Lferm-1 was inoculated into a three-mixed liquid culture medium (BHI+MRS+modified GAM) and anaerobically cultured at 37°C for 48 hours to obtain fermentation broth.
[0118] Preparation and coating of pathogens: Salmonella paratyphi B, Yersinia enterocolitica and Staphylococcus aureus are aerobic bacteria. After activation with TSB broth medium, they were diluted 50 times in TSB broth medium to reach the appropriate concentration, and 0.2 mL of the diluted bacterial solution was coated on TSA solid medium. Clostridium difficile is an anaerobic bacterium. After anaerobic activation and transfer, it was diluted 50 times in a three-mixed liquid medium (BHI+MRS+modified GAM), and 0.2 mL of the diluted bacterial solution was coated on anaerobic GAM solid medium (added with 5% horse serum, Beijing Solebow Technology Co., Ltd., S9050).
[0119] Co-cultivation of Lactobacillus mucilaginosus and pathogens: Place 3 sterilized Oxford cups on the coated pathogen plate, add 0.2 mL of Lactobacillus mucilaginosus fermentation liquid into the Oxford cups. Place in a culture box (anaerobic pathogens plus anaerobic gas production bag), place the plate upright for 24 hours, measure the size of the inhibition zone with a vernier caliper, and calculate the average value.
[0120] The results are as follows Figure 3 As shown: Fermented Lactobacillus mucilaginosus has antibacterial ability against Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile.
[0121] Example 7: In vitro cell inflammation inhibition test of fermented Lactobacillus mucilaginosus Lferm-1
[0122] THP-1 cell polarization: 1×10 cells were cultured in RPMI-1640 (Thermo Fisher, C11875500BT) medium containing 10% FBS and a final concentration of 100 ng / mL PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich Company, P1585). 5 THP-1 cells were seeded in 96-well plates at a seeding density of 10 cells / well and placed in a 5% CO 2 Incubator, culture at 37°C for 24 h to polarize them into mature macrophages.
[0123] Strain culture: Inoculate 200 μL of the fermented Lactobacillus mucilaginosus Lferm-1 culture medium from the bacterial storage into 5 mL of the mixed medium (BHI+MRS), and culture anaerobically in a 37°C electric constant temperature incubator for 24 hours. After transferring once, culture anaerobically for 8 hours. Take 1 mL of the culture medium and centrifuge at 5000 rpm / min for 15 minutes. Dilute to 2×10 with RPMI-1640 medium containing 10% FBS. 6 CFU / mL is reserved.
[0124] Effect of fermented lactobacillus Lferm-1 on the expression of TNF-α and IL-6 in THP-1 cells: After the mature THP-1 cells were cultured, the normal control group was replaced with RPMI-1640 medium containing 10% FBS; the model group, positive control group and Lferm-1 test group were replaced with RPMI-1640 medium containing 10% FBS, a final concentration of 100 ng / mL LPS (Sigma-Aldrich Company, L3024) and 20 ng / mL IFN-γ (PeproTech, AF-300-02) to model inflammatory macrophages. Each group was placed in 5% CO 2 Incubator, culture at 37℃ for 24h. The culture medium was removed, and 100μL of RPMI-1640 culture medium containing 10% FBS was added to the normal control group and the model group respectively; 100μL of RPMI-1640 culture medium containing 10% FBS and dexamethasone (purchased from Sigma-Aldrich Company, D4902-25) with a final concentration of 25μg / mL was added to the positive control group; 100μL of the fermented Lactobacillus Lferm-1 culture medium prepared in advance was added to the Lferm-1 test group. Place in 5% CO 2 After culturing in an incubator at 37°C for 24 h, 80 μL of cell culture medium was aspirated from each group, and the cells were centrifuged at 4°C, 5000 rpm / min for 15 min. The supernatant was collected and the TNF-α content was detected using a Human TNF-α (Tumor Necrosis Factor Alpha) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H0109c), and the IL-6 content was detected using a Human IL-6 (Interleukin 6) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H6156).
[0125] Experimental results: Figure 4 As shown in the results, the expression of IL-6 and TNF-α in the model group cells was significantly higher than that in the normal control group (P<0.01); the positive control dexamethasone group could significantly inhibit the expression of proinflammatory factors IL-6 and TNF-α in THP-1 cells (P<0.01); the fermented Lactobacillus mucus Lferm-1 group could also significantly reduce the expression of proinflammatory factors IL-6 and TNF-α compared with the model group (P<0.05), indicating that the strain has a certain anti-inflammatory effect in vitro.
[0126] Example 8: Therapeutic effect of fermented Lactobacillus mucilaginosus Lferm-1 on 5-FU-induced diarrhea in mice
[0127] Lyophilization protective agent preparation:
[0128] Solution A: 8g sucrose, 8g trehalose, 44g purified water, sterilized at 115℃ for 30min;
[0129] Solution B: 2g sodium glutamate, 2g arginine hydrochloride, 16g purified water, sterilized at 115℃ for 30min;
[0130] Liquid C: 4g of sodium vitamin C, 16g of purified water.
[0131] Filter and sterilize for later use. When using, mix in a volume ratio of A:B:C = 6:2:2.
[0132] Preparation of bacterial powder: The preserved fermentation mucus Lactobacillus Lferm-1 was inoculated into the bacterial powder preparation fermentation medium, and anaerobically cultured at 37°C and 90rpm to obtain a primary seed solution (OD 600 Then, the mixture was transferred to the bacterial powder to prepare the fermentation medium and anaerobically cultured at 37°C and 90 rpm to obtain the secondary seed solution (OD 600 The secondary seed liquid was pumped into the fermentation tank containing the fermentation medium prepared with bacterial powder by a peristaltic pump, and the fermentation parameters (temperature 37°C, pH=5.1, speed 100rpm, pressure control 0.06MPa) were set to start fermentation. 600 Value ≥1.5 or OD 600 When the value increases by ≤0.1, stop fermentation and collect the bacterial cells. Divide the bacterial liquid into centrifuge buckets, centrifuge and discard the supernatant. Add lyophilization protective agent at a weight ratio of 1:1 to 1:2 to emulsify the bacterial slurry. Place the emulsified bacterial suspension on a freeze dryer cooled to -40°C and freeze-dry. After the freeze-drying process is completed, take out the bacterial cake and crush it to obtain bacterial powder. Before administering the drug to the animals, use 0.2 mL of normal saline to mix 1×10 9 CFU bacterial powder is prepared into bacterial suspension.
[0133] Experimental animals: 20 SPF-grade male Balb / c mice, weighing 18-22 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF-grade animal room.
[0134] Experimental design: 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / tube, 0.25g / 10mL) solution was used to induce chemotherapy-related diarrhea model in mice. The mice were randomly divided into 4 groups according to their initial body weight, namely normal control group, model control group, positive control loperamide group and fermented Lactobacillus mucinus Lferm-1 group, with 5 mice in each group.
[0135] The total experimental period was 9 days, recorded as D1-D9. A single 5-FU model was created on D3. Except for the normal control group, which was intraperitoneally injected with normal saline, all other groups were treated with a single 5-FU intraperitoneal injection of 350 mg / kg (body weight).
[0136] All groups were given drugs by gavage. The normal control group and the model control group were given lyophilized protective agent by gavage. The positive control group was given 20 mg / kg (body weight) of loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) by gavage for 9 consecutive days (D1-D9). The Lferm-1 group was given 1×10 9 CFU fermented Lactobacillus mucilaginosus. After the end of D5 administration, the subjects were observed for 4 consecutive days. The specific experimental groups and administration schemes are shown in Table 1.
[0137] Table 1. Trial groups and dosing regimen
[0138]
[0139] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day
[0140] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.
[0141] Test results: Figure 5 As shown in the figure, compared with the model control group, the Lferm-1 administration group had a significant improvement effect on 5-FU-induced diarrhea, and the effect was comparable to that of the positive control loperamide ( Figure 5 A); both loperamide and fermented Lactobacillus mucilaginosus Lferm-1 could significantly reduce the total score of diarrhea (P<0.05) ( Figure 5 B).
[0142] Example 9: Fermented Lactobacillus mucilaginosus Lferm-1 improves colon pathological damage in mice with 5-FU-induced diarrhea
[0143] The animals of Example 8 were dissected at D10, and the mid-segment colon was collected and fixed in 4% paraformaldehyde for 24 h. The fixed colon tissue was dehydrated, transparent, waxed and embedded in sequence. The embedded colon tissue wax block was sliced to a thickness of 5 μm, then spread and baked, and the dried slices were subjected to conventional HE staining. The pathological changes were observed under an optical microscope, and the pathological scores were performed according to Table 2, and the total pathological score (the sum of the scores of each index) was calculated.
[0144] Table 2. Colon histopathology scoring indicators and descriptions
[0145]
[0146] The test results can be found in Figure 6 :like Figure 6 As shown in A, a is the normal control group, b is the model control group, c is the loperamide group, and d is the Lferm-1 group. The colon structure of the normal control group was intact, and the mucosal layer, submucosal layer, muscular layer and serosa layer were clearly visible; in the model control group, necrosis and dissolution of intestinal glands, decreased goblet cells, lymphocyte infiltration, loose connective tissue in the submucosal layer, and dilation of blood vessels were observed in the colon propria; in the loperamide group, the colon structure was relatively intact, no obvious necrosis of mucosal epithelial cells was observed, the number of goblet cells increased significantly, and only a small amount of lymphocyte infiltration was observed in the propria; in the Lferm-1 group, a small amount of mucosal epithelial cell necrosis was observed in the colon tissue, accompanied by a small amount of lymphocyte infiltration; a small amount of intestinal glands were dilated; the number of goblet cells was slightly reduced; mild edema was observed in the submucosal layer, accompanied by a small amount of lymphocyte infiltration.
[0147] Depend on Figure 6 B shows that after 5-FU induction, the mouse colon showed obvious damage. The total pathological score of the model control group was significantly higher than that of the normal control group (P<0.01). After administration of fermented mucus lactobacillus Lferm-1, the total pathological score was consistent with that of the loperamide group, which significantly reduced the total pathological score of the colon (P<0.05) and improved the degree of colon damage.
[0148] It can be seen that fermented Lactobacillus mucilaginosus Lferm-1 can significantly improve the pathological damage of mouse colon caused by 5-FU.
[0149] Example 10: Effect of fermented Lactobacillus mucilaginosus Lferm-1 on the mRNA transcription level of TNF-α in the colon of mice with 5-FU-induced diarrhea
[0150] The animals in Example 8 were dissected on D10, and the mid-segment colon was collected and stored in a -80°C refrigerator. Total RNA from the colon tissue of each group of mice was extracted according to the kit instructions, and reverse transcribed into cDNA, which was stored at -20°C for later use. The relative transcription level of TNF-α gene mRNA in the colon of each group of mice was detected by qRT-PCR (primer sequences are shown in Table 3). Reaction procedure: 95°C for 3 min, 95°C for 20 s, 60°C for 45 s, 72°C for 20 s, for a total of 39 cycles. 2 -ΔΔCT The data were analyzed by SPSS 24.0 statistical software.
[0151] Table 3. qRT-PCR primer information
[0152]
[0153] Test results see Figure 7 : Compared with the normal control group, the relative transcription level of TNF-α mRNA in the model control group was extremely significantly increased (P<0.01). The relative transcription level of TNF-α mRNA did not decrease significantly after loperamide treatment, while the administration of Lferm-1 could significantly reduce the relative transcription level of TNF-α mRNA (P<0.01).
[0154] It can be seen that the fermented Lactobacillus mucius Lferm-1 of the present invention can improve diarrhea symptoms in many aspects and has a significant therapeutic effect on chemotherapy-related diarrhea.
[0155] It is known from common technical knowledge that the present invention can be implemented by other embodiments that do not deviate from its spirit or essential features. Therefore, the above disclosed embodiments are only illustrative in all respects and are not exclusive. All changes within the scope of the present invention or within the scope equivalent to the present invention are included in the present invention.
Claims
1. A biomaterial, wherein the biomaterial is selected from the following M1, M2, M3 and M4; M1: fermented Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof; M2: progeny strain of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or its lysate; M3: a cloned strain of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof; M4: pure culture of Lactobacillus mucilaginosus with a deposit number of CCTCC NO: M2023352 or a lysate thereof.
2. A method for culturing fermented mucus Lactobacillus, the method comprising: inoculating a fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, a progeny strain of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, a cloned strain of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352, or a pure culture of the fermented mucus Lactobacillus with a deposit number of CCTCC NO: M2023352 into a culture medium, performing proliferation culture, and obtaining proliferated fermented mucus Lactobacillus.
3. A composition comprising the biomaterial according to claim 1 as an active material.
4. The composition according to claim 3, characterized in that The composition further contains auxiliary materials.
5. The composition according to claim 4, characterized in that The auxiliary material is selected from any one of the following materials: Bacterial culture medium; Lyoprotectants; Pharmaceutically acceptable carriers or excipients; Acceptable materials in health products; acceptable materials in cosmetics; Materials acceptable in food.
6. Use of the biomaterial according to claim 1 or the composition according to any one of claims 3 to 5 in the preparation of a product for use alone or in combination with other microbial agents and / or drugs to improve the health of a subject; The improving the health condition of the subject is selected from: Treat, prevent and / or relieve chemotherapy-induced diarrhea; Treating, preventing and / or slowing down chemotherapy-induced colon damage in subjects; Inhibiting the proliferation of any one, any two, any three or four of Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile in the body cavity of the subject; Treat, prevent and / or alleviate tissue damage, disease or sub-health condition caused by any one, any two, any three or four of Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile; Treating, preventing and / or alleviating tissue damage, disease or sub-health condition caused by increased expression of any one, any two or three of IFN-γ, TNF-α and IL-6; Improve the antioxidant capacity in the intestines of subjects.
7. The use according to claim 6, characterized in that The product is selected from medicines, health products, foods and cosmetics.
8. The use according to claim 6, characterized in that The subject is selected from humans and mice.
9. The use according to claim 6, characterized in that The chemotherapy drugs are selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.
10. The use according to claim 9, characterized in that The chemotherapy drug is selected from doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, 5-fluorouracil, and irinotecan.
Citation Information
Cited By
Lactobacillus acidophilus for relieving chemotherapeutic diarrhea and improving constipation and application of lactobacillus acidophilus
CN120699852A
Lactobacillus acidophilus for relieving chemotherapy-induced diarrhea and improving constipation and application thereof
CN120699852B
Lactobacillus mucilaginosus and application thereof
CN122303111A
Lactobacillus fermentum with anti-inflammatory effect and application thereof
CN122609453A
